FDA Approves Alimta for Malignant Pleural Mesothelioma
Alimta is an antifolate antineoplastic agent used in combination with cisplatin (a standard chemotherapy agent), for the treatment of malignant pleural mesothelioma (a cancer of the lining of the lungs) in patients who are not candidates for surgery.Posted: February 2004
Related articles
- Lilly Receives Fourth FDA Approval for Alimta (pemetrexed for injection) as Maintenance Therapy For Nonsquamous Non-Small Cell Lung Cancer - July 7, 2009
- FDA Grants Lilly's Alimta (Pemetrexed for Injection) Third U.S. Approval - September 29, 2008
- FDA Approves Alimta for use with cisplatin, for the treatment of Malignant Pleural Mesothelioma - February 4, 2004
Alimta (pemetrexed) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
